Chondrosarcoma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Chondrosarcoma is a rare malignant tumor that forms a cartilaginous matrix. Chondrosarcomas arising de novo are termed primary chondrosarcomas, while those developing in pre-existing benign cartilaginous tumors such as osteochondroma or enchondroma are referred to as secondary chondrosarcomas. CHS constitutes various groups of malignant bone tumors and encompasses multiple histological subtypes. Overall, conventional CHS is the most common subtype. It accounts for 85% of CHS, followed by dedifferentiated (10%), mesenchymal and clear cell CHS, these two representing less than 2% of all CHS cases. Conventional CHS can develop de novo or in a pre-existing enchondroma and osteochondroma. CHS is classified into three grades based on cellular atypia, mitotic figures, and cellularity. CHS grades 1 and 2 are represented by 85% of all CHSs, 15% of cases are grade 3, and the dedifferentiated CHS. According to the latest WHO recommendations, CHS should be classified into central or secondary peripheral atypical cartilaginous tumor/CHS (grade 1), central or secondary peripheral CHS grade 2 and 3.

  • The estimated overall incidence is 1 per 200,000/year and accounts for 20–30% of primary malignant bone tumors. The majority of cases occur after age 50, with a slight male predominance. The incidence of pediatric chondrosarcoma is less than 10% of all chondrosarcoma cases, with higher survival rates than adults.

The competitive landscape of Chondrosarcoma includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Chondrosarcoma across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Chondrosarcoma Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Chondrosarcoma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No    Asset   Company         Stage

1          pazopanib         George Clinical Pty Ltd  Phase 2

2          INBRX-109       Inhibrx, Inc.       Phase 2

3          Trabectedin       PharmaMar       Phase 2

4          AG-120 Agios Pharmaceuticals, Inc.       Phase 2

5          Perifosine         AEterna Zentaris           Phase 2

6          LY3410738       Loxo Oncology, Inc.       Phase 1

7          Enasidenib        Celgene            Phase 2

8          IGM-8444         IGM Biosciences, Inc.    Phase 1

9          FT-2102            Forma Therapeutics, Inc.           Phase 2

10        INBRX-109       Inhibrx, Inc.       Phase 1

Continued...

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypoglycemia and severe
Read more